Stock MRSN MERSANA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
2.14 USD -3.39% Intraday chart for Mersana Therapeutics, Inc. -8.15% -7.76%
May. 09 Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mersana Therapeutics to Present at Upcoming Investor Conferences
AQ
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
AQ
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
AQ
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Mersana Therapeutics to Present at Upcoming Investor Conferences
AQ
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
AQ
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
AQ
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Mersana Therapeutics : Termination of Material Agreement - Form 8-K
PU
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
AQ
Dynamic Innovators: Nano-Cap Stock Watchlist (SING, LILM, OMQS, MRSN)
AQ
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
AQ
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
AQ
Mersana Therapeutics Announces Changes in Leadership
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
PR
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRSN Stock
  4. News Mersana Therapeutics, Inc.
  5. Press Releases